NEW YORK, January 10, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), Dendreon Corp. (NASDAQ: DNDN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Impax Laboratories Inc. (NASDAQ: IPXL) and Anika Therapeutics, Inc. (NASDAQ: ANIK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ACADIA Pharmaceuticals, Inc. Research Report
On January 7, 2014, Acadia Pharmaceuticals, Inc.'s (Acadia) stock ended trading at $23.61, compared to the previous day's closing price of $24.70, representing a 4.41% decline. The Company's stock went down by 6.12% over the past three trading days, compared to the Dow Jones Industrial Average, which went up by 0.54% over the same trading period. The Full Research Report on ACADIA Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://analystscorner.com/microwriter/link.php's=DDD
http://www.analystscorner.com/r/full_research_report/3eb7_ACAD
--
Dendreon Corp. Research Report
On January 7, 2014, Dendreon Corp. (Dendreon) announced that a presentation by its management is scheduled at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 16, 2014 at 1:00 p.m. PT. The Company added that the presentation will be webcast live and available for replay at Dendreon's website. The Full Research Report on Dendreon Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://analystscorner.com/microwriter/link.php's=
http://www.analystscorner.com/r/full_research_report/de0c_DNDN
--
Cell Therapeutics, Inc. Research Report
On January 6, 2014, Cell Therapeutics, Inc. (CTI) announced the issuance of Final Appraisal Determination (FAD) by National Institute for Health and Care Excellence's (NICE) for PIXUVRI® (pixantrone) for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. James A. Bianco, M.D., President and CEO of CTI stated, "The positive recommendation by NICE for the funding of PIXUVRI means that physicians in England and Wales now have access to the only approved therapy for their patients with aggressive B-cell NHL in the third- and fourth-line salvage setting." CTI stated that it anticipates the official launch PIXUVRI in England and Wales in early spring, when the FAD has been largely implemented. The Full Research Report on Cell Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://analystscorner.com/microwriter/link.php's=
http://www.analystscorner.com/r/full_research_report/f9df_CTIC
--
Impax Laboratories Inc. Research Report
On January 7, 2014, Impax Laboratories Inc. (Impax) announced that it has entered into an agreement with Durect Corp. (Durect) under which Impax has been granted the exclusive worldwide rights for developing and commercializing ELADUR®- Durect's investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia. The Company informed that according to the agreement, Impax will pay an upfront fee of $2 million to Durect, with possible additional payments of up to $61 million after the achievement of milestones related to predefined development and commercialization. Michael Nestor, President of Impax, commented, "This agreement is another example of our commitment to building a strong brand pipeline through internal R&D and external business development. We are excited to collaborate with DURECT as this product could, if approved, fit well with the capabilities of our neurology focused specialty sales force." The Full Research Report on Impax Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://analystscorner.com/microwriter/link.php's=
http://www.analystscorner.com/r/full_research_report/4c54_IPXL
--
Anika Therapeutics, Inc. Research Report
On January 7, 2014, Anika Therapeutics, Inc.'s (Anika) stock closed at $34.75, compared to the previous day's closing price at $35.36, representing a 1.73% decline. The Company's stock went down 0.69% over the past three trading days, compared to the Dow Jones Industrial Average, which advanced 0.54% over the same trading period. The Full Research Report on Anika Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://analystscorner.com/microwriter/link.php's=
http://www.analystscorner.com/r/full_research_report/ae5d_ANIK
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
